Clinuvel reports cessation of securities

Clinuvel Pharmaceuticals Limited (CUVL) furnished an Appendix 3H notification titled “Notification of cessation of securities,” which it filed with the Australian Securities Exchange on October 15, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/15/2026 - 06:07 AM EDT Accepted by SEC EDGAR 10/15/2026 - 06:02 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-43353

CLINUVEL PHARMACEUTICALS LIMITED

Level 22, 535 Bourke Street

Melbourne, VIC 3000

Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On October 15, 2026, Clinuvel Pharmaceuticals Limited filed the following documents with the Australian Securities Exchange are furnished to this Form 6-K as Exhibit 99.1.

Exhibits

Exhibit No.		Description

99.1		Appendix 3H - Notification of cessation of securities

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CLINUVEL PHARMACEUTICALS LIMITED

Date: October 15, 2026	By:	/s/ Philippe Wolgen
	Name:	Philippe Wolgen
	Title:	Managing Director and Chief Executive Officer